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(IPVC) is the most important event in the field of
cervical cancer prevention and control. It is held
under the auspices of the International Papilloma-
virus Society. The 27th IPVC was held September
17–22, 2011 in Berlin, Germany. More than 2000
participants from 78 countries attended the con-
ference. A total of 870 abstracts were presented
in either oral or poster format. In light of the
importance of cervical cancer as a major public
health problem in sub-Saharan Africa (SSA), the
27th IPVC presentations that focused on this region
are summarized below. Several presentations dealt2
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2.04.001with issues related to human papillomavirus (HPV)
vaccine acceptability and cost, as well as with bur-
den of HPV infection prevalence, particularly
among HIV-infected patients.
At the opening ceremony, one of the conference
keynote speakers, Dr. Rose Anorlu, Lagos, Nigeria,
discussed the current burden of HPV and cervical
cancer in SSA [1,2]. Incidence and mortality rates
for invasive cervical cancer rates in SSA are the
highest in the world at 56 and 41 per 100,000
women annually, respectively [3]. However, this
might be an underestimate, as only 8% of the SSA
population is covered by cancer registries. Owing
to fragile health care systems, lack of screening
programmes, treatment facilities, and to the HIVn behalf of Ministry of Health, Saudi Arabia.
creativecommons.org/licenses/by-nc-nd/4.0/).
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The high coverage of Rwandas national HPV vac-
cination programme [4] among school students
aged 11–15 years was one of the highlights from
this conference, and now serves as a useful model
for limited-resource settings. In Tanzania, Remes
et al. [5] and Watson-Jones et al. [6] examined
knowledge, attitudes, and acceptability concern-
ing HPV vaccination among teachers, parents, fe-
male students, female nurses, and religious
leaders. They described a cluster-randomized trial
of school-based HPV vaccine delivery strategies in
the same country. Both approaches – class-based
and age-based – were highly acceptable, but
class-based delivery attained higher coverage than
the age-based strategy. The study also identified
potential predictors of coverage failure: school
absenteeism and parental refusal being the most
important. Nurses in Tanzania had a low level of
knowledge regarding cervical cancer. The rest of
the study participants had no knowledge of cervical
cancer, HPV, or HPV vaccination [5].
In South Africa, Delany-Moretlwe et al. [7]
interviewed key informants, parents, community
members, and learners. They also conducted fo-
cus group discussions with learners, teachers
and health-care providers. Using qualitative and
pair-wise ranking methods, Delany-Moretlwe
et al. [8] assessed the feasibility and acceptabil-
ity of introducing the HPV vaccine at urban and
rural settings in South Africa. In the urban set-
ting, the first two priorities included: (i) referral
for circumcision, and (ii) information, screening
and referral for child abuse. Participants from
the rural setting gave priority to: (i) information,
screening and referral for tobacco and alcohol
abuse, and (ii) screening for hearing or vision.
Both settings identified similar third and fourth
priorities: screening and referral for sexual and
reproductive health, and screening and referral
for anxiety and depression, respectively. In South
Africa [7], all participants identified vaccine
delivery strategies as an important gap and con-
cern. However, some recommended addressing
sexual health issues when presenting the vaccine,
while others preferred using the approach of mar-
keting the vaccine as a cervical cancer preven-
tion tool.
In both countries there was a high rate of accep-
tance for the vaccine [5–7], especially in the ab-
sence of a cervical screening programme [7].
However, many respondents expressed some con-
cern surrounding side-effects [5–7], including the
risk of infertility following vaccination [5].Cost of HPV vaccination was an important con-
cern in the SSA. In a vaccination campaign involving
13-year-old girls attending schools in the Mwanza
region in Tanzania, Quentin et al. [9] estimated a
cost of US$ 35 for delivering one dose of the vac-
cine, including the US$ 5 vaccine cost. Most of
the cost is related to administrative, training and
supervision (50%) and vaccination costs (30%).
Levin et al. [10] examined delivery costs for HPV
vaccination in an outreach-based programme in
Uganda, a school in Vietnam, and campaigns in
Peru and India. In these settings, the delivery cost
(per dose) was estimated at US$ 1.4, 4.7 and 2.7,
respectively.
HPV vaccination campaigns might vary depend-
ing on country and context. The Global Alliance
for Vaccines and Immunization (GAVI) will share
the cost of HPV vaccination for 56 listed countries
[11] that have a Gross National Income (GNI) per
capita below or equal to US$ 1500. In November
2011, GAVI alliance members met in Dhaka, Sene-
gal, and made the commitment to vaccinate up
to 2 million girls and women in SSA by the year
2015. Effective roll-out of vaccination in this region
will certainly benefit from the opinions and exper-
tise of those working in the field, or conducting re-
search in SSA, and is essential for ensuring high
uptake. Professor Harald zur Hausen, Nobel Prize
Laureate for Medicine in 2008 for discovering the
link between HPV and cervical cancer, has been a
champion in the fight against cervical cancer in
SSA and has stated [12]:
‘‘...I am delighted to see the HPV vaccine on its way
to protect many lives. In developing countries girls
and women often have only very limited access to
screenings and medical treatment, so the vaccine will
play a crucial role in the fight against cervical
cancer...’’
Regarding the burden of HPV infection by geno-
types, HPV 16 was the predominant HPV type iden-
tified in four studies conducted in Eastern and
Southern Africa (Kenya [13] 18%; Uganda [14] 6%;
Zimbabwe [15] 27% and South Africa [16] 18%).
However, there was some discordance among the
regions. For example, HPV 56 was the dominant
type in Kenya (19%), whereas HPV 58 was the dom-
inant type (tied with HPV 16) in Zimbabwe (27%).
Prevalence of HPV is often much higher among
HIV patients. Maranga et al. [13] reported types
56, 52 and 58 as the most prevalent (19%, 17%
and 15%, respectively) followed by type 16 (12%)
in a group of HIV-positive subjects from Kenya.
Wang et al. [16] reported types 16 and 35 as the
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HIV-positive women in Cape Town, South Africa. In
comparison with other prevalent types, infection
with these two types was associated with a twofold
elevated risk of developing high-grade cervical
lesions.
To investigate the rate of HPV acquisition and
clearance, Mbulawa et al. [17] enrolled HIV-posi-
tive and HIV-negative women and men in Cape
Town, South Africa, and followed them for two
years. At study enrolment [18], genital HPV preva-
lence was 75% and 35% among HIV positive and
negative women, respectively. For men, HPV prev-
alence was 80% and 50% among HIV positive and
negative individuals, respectively. For both sexes,
the differences in HPV prevalence were statisti-
cally significant. HIV-positive individuals (both wo-
men and men) were less likely to clear their HPV
infection relative to their HIV-negative peers
[16]. Additionally, women with abnormal cervical
cytology were less likely to clear their HPV infec-
tion relative to those with normal pap smears.
Being HIV positive with a high HIV viral load was a
risk factor for HPV infection, acquisition, and per-
sistence in both genders. However, HIV-positive
men had a significantly higher risk of acquiring both
high-oncogenic-risk or low-oncogenic-risk HPV
types than the HIV-negative men.
Weiderpass et al. [14] assessed HPV prevalence
among women who were screened positive at
visual inspection and were invited for a colposcopy.
Approximately 40% and 16% tested positive for HPV
and HIV respectively. In comparison to HPV+/HIV
women, investigators found that co-infected wo-
men were at higher risk for developing new high-
oncogenic-risk HPV infections [14,16]. Finally, Tra-
cy et al. [19] compared HPV prevalence between
rural and urban women living in Mali and found a sig-
nificant difference (23% versus 12%, respectively).
Rural women self-reported having >1 sexual partner
before reaching age 20, andalso tended to be more
open to polygamous relationships.
The 28th IPVC will take place in Puerto Rico in
2012 (www.hpv2012pr.org). The organizers are
encouraging investigators from SSA to submit their
work, especially studies describing the introduc-
tion of HPV vaccinations in different settings and
contexts.Additional learning material on cervical
cancer prevention
An online oncology course, developed by the Cata-
lan Institute for Oncology; the course is accessible
for free (http://www.e-oncologia.org/en/curso).All educational presentations of the Clinical and
Public Health Workshops can be accessed and
viewed as a webcast for free at the congress
website (http://www.hpv2011.org/webcast/inhal-
t.asp) in addition to comprehensive summaries
for all presentations [20–22].
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